Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Paula Francezca C. Padua

Paula Francezca C. Padua

St. Luke’s Medical Center, Philippines

Title: Venolymphatic malformation in a 4 year old male, treated with picibanil (ok-432) with systemic inflammatory response syndrome as a complication: A Case Report

Biography

Biography: Paula Francezca C. Padua

Abstract

Objective:

(1) To present a case of venolymphatic malformation and OK-432 as its management

(2) To discuss the mechanism of action of OK-432 in the treatment of        venolymphatic malformations

(3) To discuss the known complications of OK-432 in the treatment of venolymphatic malformations

Design:  Case Report

Setting:  Tertiary Hospital in Metro Manila

Case Report: A 4 year old male, presenting with a right facial and cervicothoracic mass, consulted and given Picibanil (OK-432) as trial treatment for 2 doses.  A local inflammatory response was observed after the first dose.  However, the patient exhibited a systemic inflammatory response after the 2nd dose.

Conclusion: Venolymphatic malformation is one of the most common types of vascular malformations with an overall prevalence of up to 1% in the general population.  Although benign, these lesions have a tendency to grow in an infiltrating manner.  OK-432, which is the most widely used alternative treatment, showed promising results of regression of malformations, systemic inflammatory response syndrome may be a possible side effect with its use.